Meeting
2024 ASCO Genitourinary Cancers Symposium
Comparison of financial toxicity among patients with non-metastatic versus metastatic renal cell carcinoma.
Authors
Michael D. Staehler
University Hospital of Munich, Munich, Germany
Michael D. Staehler , Ulka N. Vaishampayan , Sumanta Kumar Pal , Pavlos Msaouel , Ithaar Derweesh , Dena Battle
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 408)
DOI
10.1200/JCO.2024.42.4_suppl.408
Abstract #
408
Poster Bd #
G11
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Quality Care Symposium
Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy.
First Author: Syed N. Rahman
Poster
2023 ASCO Quality Care Symposium
National service is free, not cancer disease: Financial toxicity in a public universal coverage healthcare system.
First Author: Paola Russo
Poster
2023 ASCO Genitourinary Cancers Symposium
Financial toxicity in patients with metastatic renal cell carcinoma on combination therapy.
First Author: Michael D. Staehler
Poster
2024 ASCO Genitourinary Cancers Symposium
Financial toxicity from PARP inhibitors in castrate-resistant prostate cancer.
First Author: David Joseph Benjamin